Literature DB >> 17074932

Important steps in the development of cognitive-enhancing drugs in schizophrenia.

Robert W Buchanan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074932     DOI: 10.1176/ajp.2006.163.11.1867

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  4 in total

1.  High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: a case series.

Authors:  Arielle D Stanford; Cheryl Corcoran; Peter Bulow; Sarah Bellovin-Weiss; Dolores Malaspina; Sarah H Lisanby
Journal:  J ECT       Date:  2011-03       Impact factor: 3.635

2.  Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.

Authors:  Christine E Marx; Richard S E Keefe; Robert W Buchanan; Robert M Hamer; Jason D Kilts; Daniel W Bradford; Jennifer L Strauss; Jennifer C Naylor; Victoria M Payne; Jeffrey A Lieberman; Adam J Savitz; Linda A Leimone; Lawrence Dunn; Patrizia Porcu; A Leslie Morrow; Lawrence J Shampine
Journal:  Neuropsychopharmacology       Date:  2009-04-01       Impact factor: 7.853

3.  The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Authors:  George Haig; Deli Wang; Ahmed A Othman; Jun Zhao
Journal:  Neuropsychopharmacology       Date:  2016-06-20       Impact factor: 7.853

4.  Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice.

Authors:  Peiyan Wong; Cecilia Chin Roei Chang; Christine E Marx; Marc G Caron; William C Wetsel; Xiaodong Zhang
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.